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Release of lysosomal enzymes from phagocytic leukocytes in the presence of vari- 
ous immune reactants is well documented  (1-6). The tissue injury that results from 
the accumulation of, and phagocytosis by, granulocytes is probably a  direct conse- 
quence of the extracellular  release  of granule  constituents  (7,  8).  Indeed,  lysosome 
granules proteins are capable of mediating inflammation (9,  10) and cartilage degra- 
dation (11-13). 
The anti-inflammatory action of certain catecholamines in various animal models 
of acute (14,  15) and chronic inflammation (16,  17) has been reported. In fact, cate- 
cholamines have been thought to play a regulatory role in the inflammatory process 
(18).  More recent  studies  have uncovered specific  actions of catecholamines at the 
cellular  and  organelle  level.  For  example,  certain  sympathomimetic  amines  were 
reported to inhibit the allergic  release of histamine from sensitized human leukocytes 
(19) and lung fragments (20).  In both of these studies it was suggested that the ac- 
tions of the catecholamines were mediated by cyclic AMP. Release of enzymes from 
isolated lysosomes was also inhibited  by epinephrine,  norepinephrine,  isoproterenol, 
theophylline,  and  cyclic  AMP  (21-24). 
In  order  to  understand  more  completely  the  anti-inflammatory  effects  of 
catecholamines at the cellular level, several adrenergic and cholinergic amines 
and cyclic nucleotides were tested  for their  capacity to modify the release  of 
/~-glucuronidase,  a  lysosomal marker  enzyme,  from and  particle  ingestion  by 
human  neutrophils  during  phagocytic uptake  of serum-treated  zymosan par- 
ticles.  In  addition,  the  effects  of  autonomic  neurohormones  on  neutrophil 
levels of cyclic AMP and  cyclic GMP were determined  in order to assess  the 
possible involvement of cyclic nucleotides in mediating the actions of the neuro- 
hormones  on phagocytic enzyme release.  Preliminary  reports  of some  of the 
present  findings  appeared  earlier  (25,  26). 
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Materials and Methods 
Isolation  of Human  Neutrophils and  Mixed  Leukocytes.--Human  neutrophils were  iso- 
lated from fresh heparinized venous blood drawn from healthy volunteers by a modification 
of the glass bead column purification procedure described by Rabinowitz (27). Briefly, leuko- 
cyte-rich plasma was obtained from heparinized blood after sedimentation of erythrocytes 
in 0.5%  (wt/vol) Dextran 2130 C  (Sigma Chemical Co., St. Louis, Mo.) in saline. The leuko- 
cyte-rich plasma was placed on the siliconized glass bead column and incubated at 37°C  for 
90 min. Lymphocytes, erythrocytes, and platelets were eluted with 50%  (vol/vol) Eagle's 
minimum essential medium in autologous plasma.  Neutrophils were  then eluted from  the 
column with 0.1 M sodium phosphate buffer, pH 7.3, containing 0.1% (w t/vol) glucose. EDTA 
was not employed in any step. The final cell suspension was prepared in Hanks' balanced salt 
solution containing 0.1% (wt/vol) glucose (HBSS) 1 and diluted to  5 X  l0 s  neutrophils  per 
ml. This procedure yielded consistently a cell suspension containing at least 97% neutrophils. 
Mononuclear cells were present to the extent of only 1-3%, and erythrocytes and platelets 
were absent. Viability of the neutrophils was always greater than 990/0 (trypan blue or eosin 
Y  exclusion) and recoveries of neutrophils from leukocyte-rich plasma was 25-45%. Human 
mixed leukocytes were obtained from heparinized venous blood after sedimentation of eryth- 
rocytes in a suspension consisting of five parts of blood mixed with one part of 6% (wt/vol) 
Dextran 70. After centrifuging the upper leukocyte layer (150 g for 10 min), cell sediments 
were washed with and then resuspended in HBSS. The final cell concentration was adjusted 
to 5 X  l0 s mixed leukocytes per  ml. Microscopic examination revealed 60-75% neutrophils, 
and over 99% of the granulocytes excluded trypan blue. 
Preparation  of Zymosan  Particles.--Zymosan  particles  (Sigma),  measuring  0.5-3  /z  in 
diameter, were suspended and boiled for 10 min in HBSS  (10  mg/ml). The supernate was 
discarded and the zymosan particle sediment was completely resuspended in either normal 
or rheumatoid arthritic serum to the extent of 25 mg/ml. High titer (1:10,240-1:20,480 by 
rheumatoid factor latex agglutination) rheumatoid arthritic (RA) serum was obtained from 
individuals with active rheumatoid arthritis. Zymosan suspensions were  then incubated at 
37°C for 30 min, while shaking adequately to maintain the particles in suspension, and the 
particles were allowed to settle. Supernates were discarded, sediments were washed extensively 
with cold saline, and resuspended thoroughly in HBSS  (10 mg/ml) with the aid of a  glass 
tissue grinder equipped with a  teflon pestle. All particle suspensions were completely homo- 
geneous and absence of particle aggregation was confirmed by phase contrast microscopy. 
Each ml of final zymosan suspension contained approximately 4  )< 10 s particles. In some 
experiments the particle concentration was varied from 0.25 X  l0 s to 4 X  10 s particles per 
ml. 
Preparation of Zymosan-Treated Serum.--Zymosan particles  (0.5-3  /z in  diameter)  were 
suspended  and boiled for  10  rain in safine  (10 mg/ml).  The sediment was  resuspended in 
0.01 M  sodium phosphate-buffered (pH 7.4)  saline, containing 0.001 M  magnesium chloride. 
The zymosan suspension (10 mg/ml) was then diluted fivefold with fresh human serum and 
incubated at 37°C for 20 rain while shaking gently. Incubations were followed by rapid filtra- 
tion through a  0.22  /z  (pore diameter)  Millipore filter. Epsilon aminocaproic acid  was  dis- 
solved in the zymosan-treated serum, to a final concentration of 0.2 M, in order to retard the 
possible loss of lysosomal enzyme releasing activity from the activated serum by a  serum 
carboxypeptidase-like enzyme(s)  (28).  The above procedure is similar to  that reported  re- 
cently by Goldstein et al. (29). 
Incubation Conditions.--Neutrophils  (5 X  106 in 1.0 ml of HBSS) were  incubated at 37°C 
1Abbreviations used in  this paper: HBSS,  Hanks'  balanced  salt  solution  containing 
0.1% wt/vol glucose; RA, rheumatoid arthritic. L.  J.  IGNARRO,  T.  F.  LINT,  AND  W.  J.  GEORGE  1397 
in a Dubnoff metabolic shaker while agitating at 120 excursions per min. Zymosan particles, 
either untreated or treated with normal or rheumatoid arthritic serum, were added to the ex- 
tent of 0.1 ml of particle suspension to 1.0 ml of cell suspension. In  those experiments where 
drugs were tested, cells and appropriate drug(s) were preincubated at 37°C  for 5  rain before 
the addition of zymosan particles and then further incubated at 37°C for 15 rain. Following 
incubation the samples were centrifuged at 350 g for 10 rain at 4°C and the supernates were 
assayed  for /3-glucuronidase and  lactate  dehydrogenase activities. 
Enzyme Assays.--/3-glucuronidase activity was measured by a  modification of the proce- 
dure reported by Gianetto and DeDuve  (30).  Aliquots  (0.2  ml)  of  supernates, obtained as 
described above, were incubated in 4.0 ml of 0.1 M  sodium citrate, pH 4.8, containing 5.0 mg 
of phenolphthalein glucuronide as substrate, at 37°C  for 18 h. Enzyme reactions were termi- 
nated by adding 0.4 ml of alkaline glycine-maleate and absorbancy (540 nm) was determined. 
Data are expressed as/~g of phenolphthalein liberated per 18 h of incubation. Lactate dehy- 
drogenase activity was measured according to the method of Bergmeyer et al. (31). Data were 
calculated as the change (A) in absorbancy at 366 nm per rain. Determinations of total neu- 
trophil enzyme activities were made after cell lysis by eight freeze-thaw cycles, employing a 
dry ice-acetone mixture, and running cool tap water. Broken cell preparations were incubated 
and centrifuged, as with intact cell preparations, and enzyme activities were then determined. 
Measurement of Particle Uptake.--Uptake  of zymosan particles by neutrophils,  present 
in either the purified neutrophil or mixed leukocyte suspensions, was quantitated by enumera- 
tion of ingested zymosan particles by oil immersion phase contrast microscopy. The data are 
expressed as the average number of zymosan particles ingested per 100 neutrophils (phagocy- 
tic index), and was calculated from 200-400 cell counts on successive microscopic fields.  This 
method can be employed to measure both the rate and the extent of phagocytosis of zymosan 
particles. In addition, in those circumstances where phagocytosis was either just beginning or 
proceeding at a reduced capacity, the percent of neutrophils which contained one or more zy- 
mosan particles was determined. 
Measurement of Neutrophil Levels of Cyclic AMP and Cyclic GMP.--Cyclic AMP  levels 
in neutrophils were measured by the protein-binding procedure described by Gilman  (32). 
Levels  of  cyclic  GMP  were  measured  essentially  according  to  the  radioimmunoassay  of 
Steiner et al. (33).  Neutrophil samples were processed by rapid freezing of individual incuba- 
tion  mixtures  containing cells,  acidification,  and  ether  extraction  as  described  previously 
(34).  Cyclic nucleotide levels in entire incubation mixtures were  determined and  the data 
are expressed as pmoles of cyclic nucleotide per 108 neutrophils. 
Drug Solutions and Sources.--Solutions  of the catecholamines contained 0.01%  (wt/vol) 
sodium metabisulfite to prevent spontaneous oxidation and were utilized within 10 rain  of 
preparation. All other solutions of test agents were prepared fresh and used within 15 rain. 
The complete names of all the chemical agents and drugs, including their salts, used in this 
study are indicated below.  The following agents were purchased from  Sigma Chemical: l- 
epinephrine  bitartrate,  l-phenylephrine  hydrochloride,  acetylcholine  chloride,  acetyl  /3- 
methyleholine chloride, carbamylcholine chloride, pilocarpine hydrochloride, choline chloride, 
atropine sulfate, hexamethonium bromide, d-tubocurarine chloride, theophylline, cyclic 3', 5'- 
adenosine monophosphate sodium,  Nc,O2r-dibutyryl  cyclic 3',5'-adenosine monophosphate 
sodium, adenosine 5'-monophosphate sodium, cyclic 3 ~  , 5'-guanosine monophosphate sodium, 
N2,&'-dibutyryl  cyclic  3',5~-guanosine  monophosphate  sodium,  guanosine  5'-monophos- 
phate sodium. The/-isomer of isoproterenol hydrochloride was obtained from Aldrich Chem- 
ical  Co.  (Milwaukee,  Wis.).  8-azido  cyclic  3P,5'-adenosine  monophosphate  and  8-bromo 
cyclic 3',5'-guanosine monophosphate  sodium,  respectively,  were  purchased  from  Plenum 
Scientific Research, Inc. (Hackensack, N. J.)  and  ICN.  Corp.  (Irvine, Calif.). CIBA-GEIGY 
Corp.  supplied  phentolamine methanesulfonate and  Ayerst provided dl-propranolol hydro- 
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RESULTS 
Release of Enzymes and Particle  Uptake  by Human Neutrophils  in the Pres- 
ence of Zymosan.--The data in Table I illustrate that both human neutrophils 
and mixed leukocytes release /3-glucuronidase into the  extracellular medium 
during uptake  or phagocytosis of serum-treated zymosan particles.  More  /3- 
glucuronidase release from, and particle uptake by, cells occurs in the presence 
of zymosan particles treated with serum from RA than from normal individuals. 
Very little release of/3-glucuronidase and uptake of particles are evident in the 
presence of serum-free zymosan. Even less  enzyme release occurs in  the  ab- 
sence of zymosan particles. In addition to the absence of significant release of 
the cytoplasmic marker enzyme lactate dehydrogenase (Table I), 99 % of the 
neutrophils  and  granulocytes in  the  mixed  leukocyte preparations  exclude 
trypan blue after 15-30  rain of incubation. Therefore, release of/3-glucuroni- 
dase represents a  selective process without concomitant loss  of cell viability. 
TABLE  I 
Release of Enzymes from and Particle Uptake by Human Neutrophils in the Presence of 
Zymosan* 
Experimental conditioner 
Neutrophils 
Cells alone 
Cells +  zymosan 
Cells +  zymosan-nor- 
mal serum 
Ceils +  zymosan-RA 
serum 
Mixed leukocytes 
Cells alone 
Cells +  zymosan 
Cells +  zymosan-nor- 
mal serum 
Cells +  zymosan-Ra 
serum 
Release of enzymes§ 
fl-glucuronidase 
4.1  -4-  0.2  (1.4) 
8.7  -4-  0.3  (3.0) 
37.2  -4-  1.9  (12.7) 
59.5  +  3.7  (20.2) 
2.8  -4-  0.4  (1.4) 
4.1  ±  0.4  (2.0) 
16.9  -4-  1.4  (8.2) 
27.4  q-  1.9  (13.3) 
Lactate dehydrogenase 
0.0029  :t:  0.0003  (2.2) 
0.0018  4-  0.0002  (1.4) 
0.0022  -4-  0.0003  (1.7) 
0.0017  -4-  0.0001  (1.3) 
0.0026  -4-  0.0004  (2.4) 
0.0031  4-0.0004  (2.8) 
0.0034  -4-  0.0003  (3.1) 
0.0028  -4-  0.0003  (2.6) 
Particle uptake 
no. partides/lO0 
neutrophils 
27-4-5 
325  ~  38 
504  4-  62 
2O-4-4 
312  -4-  41 
506  -4-  66 
* Data represent the Mean -4- SEM of three to five separate experiments. 
Cells (5  X  106) were incubated at 37°C for 15 min as indicated. 
§/3-glucuronidase activity is expressed as/zg phenolphthalein/18 h/5 X  106  total  cells; 
values for total cell activity were 294 4- 12  (neutrophils) and 206 -4- 14  (mixed leukocytes). 
Lactate  dehydrogenase activity is expressed as  Aabsorbancy  (366  nm)/min/5  X  106  total 
cells;  values  for  total  cell  activity  were  0.131  -4- 0.008  (neutrophils)  and  0.109 :t: 0.010 
(mixed leukocytes). Numbers in parentheses signify percent of total cell enzyme activity. L. J. IGNARRO, T. F. LINT, AND W. J. GEORGE  1399 
Neutrophils  and  mixed  leukocytes respond  to zymosan particles  in  a  quali- 
tatively similar manner with regard to particle uptake and enzyme release. 
In  the  presence  of zymosan  particles  treated  with  RA  serum,  release  of 
/~-glucuronidase from neutrophils is detectable  after 5 min of incubation  and 
increases markedly during  the following 10 min  (Fig.  1). Enzyme release ap- 
pears to taper off by 20-30 min, although a small increment of enzyme release 
continues during incubation of cells for an additional 3 h  (data not illustrated). 
Particle uptake starts almost immediately and increases linearly through  the 
first 10 min of incubation, after which time particle ingestion begins to attain 
a  maximum (Fig.  1).  Over 80% of the neutrophils  take up one or more par- 
tides at each time interval except 2 rain where approximately 45 % of the cells 
ingest  particles.  These data  illustrate  a  close  temporal relationship  between 
discharge of/3-glucuronidase into and ingestion of zymosan particles from the 
extracellular  environment.  Thus,  release  of  /3-glucuronidase  occurs  during 
phagocytosis and not subsequent to attainment of maximum particle uptake. 
These findings are similar to those reported previously which indicated  a  cor- 
relation between the extracellular appearance of granule enzyme and the time 
of phagocytosis (35,  36). Lactate dehydrogenase is not released to any signifi- 
cant extent during 30 min of incubation. In fact, no significant release of lactate 
dehydrogenase from neutrophils  occurs until  6-8 h  of incubation  at 37°C,  at 
which  time a  significant number of cells begin  to take up  trypan blue.  It is 
important to indicate that neither normal serum nor RA serum, undiluted  or 
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FIG. 1. Release of/3-glucuronidase and lactate dehydrogenase from and particle uptake by 
human neutrophils in the presence of zymosan. Neutrophils  (5 X  106) were incubated at 
37°C in 1.0 ml of HBSS containing 4 X  108 zymosan particles treated with  rheumatoid ar- 
thritic serum (particle/cell ratio was 80). Values for total cell enzyme activities, determined 
after lysis of cells by freezing and thawing, were 288 -4- 15 #g phenolphthalein/18 h/5 X  106 
neutrophils for  /3-glucuronidase and  0.139 -4- 0.011 Aabsorhancy  (366 nm)/min/5 X  10 s 
neutrophils for lactate dehydrogenase. Data represent the Mean -4- SEM of three separate 
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diluted 10-fold, provoked release of/~-glucuronidase from neutrophils or mixed 
leukocytes in the absence of zymosan particles. 
The  close  relationship between /5-glucuronidase release  and zymosan par- 
ticle uptake, under conditions where the particle per cell ratio was varied, is 
illustrated in Fig. 2. Over 85 % of the neutrophils ingest one or more particle 
at each particle/cell ratio except five where 60-80 % of the cells take up par- 
ticles. Lactate dehydrogenase is not discharged regardless of the numbers of 
particles associated with neutrophils. 
In order to assess the possible role of complement components in provoking 
the sera-treated zymosan-induced release of fl-glucuronidase from, and particle 
uptake by, human neutrophils sera were heated at 53°C for 30 rain before in- 
cubation with zymosan particles. Particle uptake and release of/~-glucuronidase 
are reduced by about 45-60%  when neutrophils are incubated with zymosan 
particles  treated  with  heated  normal  serum  (Table  II).  However,  zymosan 
treated with heated RA serum provokes the same degree of particle uptake and 
enzyme release as does zymosan treated with unheated RA serum. Therefore, 
RA serum appears to be heat-resistant with regard to its capacity to promote 
zymosan-induced phagocytosis by, and lysosomal enzyme release from, human 
neutrophits. 
Effect of Catecholamines and Cyclic AMP on Release o/~-Glucuronidase  from 
and Particle  Uptake  by  Human  Neutrophils.--Epinephrine  and  isoproterenol 
inhibit release of/3-glucuronidase from, and particle uptake by, neutrophils in 
the presence of zymosan treated with RA serum (Table III). Phenylephrine, a 
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FIG. 2. Effect of particle/cell ratio on release of ~-glucuronidase and lactate dehydrogenase 
from and particle uptake  by human neutrophils in  the presence of zymosan. Neutrophils 
(5 X  106) were incubated at 37°C for 10 mill inl.0 ml of HBSS containing various numbers 
of zymosan particles treated with rheumatoid arthritic serum. Values for total cell enzyme 
activities, determined after lysis of cells by freezing and thawing, were 308 --t- 19 #g phenol- 
phthalein/18  h/5 X  106  neutrophils for ~-glucuronidase and 0.125  ~  0.009  Aabsorbancy 
(366 nm)/min/5 X  106 neutrophils for lactate  dehydrogenase. Data  represent the Mean ~- 
SEM of four separate experiments. L. J. IGNARRO,  T. ]~. LINT, AND  W. J. GEORGE  1401 
TABLE  II 
Effect of Heated and Cobra Venom Factor-Treated Sera on Particle Uptake by and [3-Glucuroni- 
dase Release from Human Neutropkits* 
Experimental conditioner  Particle uptake  /~-glucuronidase release 
5 X  l0 s neutrophils (N) 
N +  zymosan (Z) 
N  q- normal serum-treated Z (NSZ) 
N  q- heated NSZ 
N  4- cobra venom factor-treated NSZ 
N  4- rheumatoid arthritic serum-treated Z 
(RASZ) 
N  +  heated RASZ 
N +  cobra venom factor-treated RASZ 
no. partides/lO0  j*g/18 k/5 X  10  s cells 
neutropkils 
--  3.6  4-  0.8 
21  4-  5  7.3  4-  0.6 
334  4-  34  40.2  4-  2.3 
140  4-  21§  24.3  4- 3.2§ 
112  4-  16§  14.8  4-  2.1§ 
528  4-  60  55.6  4- 4.1 
506  4-  44  49.9  4- 3.7 
468  4-  49  47.2  4-  4.6 
* Data represent the Mean 4- SEM of four separate determinations. Incubations were 
conducted at 37°C for 15 min as indicated. 
Heated sera were prepared by heating fresh sera at 56°C for 30 min. Zymosan particles 
were treated with heated sera in the same manner as for unheated sera. 10 U of cobra venom 
factor (0.1 ml of stock 100 U per ml) were mixed with each ml of the sera and incubated at 
30°C for 60 min. Zymosan particles were treated with cobra venom factor-treated sera in the 
same manner as for untreated sera. 
§ Significantly  different (P <  0.001) from  corresponding  controls (N -[- normal serum- 
treated Z). 
related  amine  but  lacking /~-adrenergic receptor  stimulating  activity, affects 
neither enzyme release nor particle uptake. Propranolol, a/~-adrenergic receptor 
antagonist, but not phentolamine, an a-adrenergic receptor antagonist, blocks 
the  inhibitory action  of  epinephrine  on  enzyme  release  and  particle uptake. 
Theophylline, which is well known  to inhibit the phosphodiesterase-catalyzed 
degradation  of  endogenous  cyclic AMP  and  thereby  elevate  tissue  levels  of 
this cyclic nucleotide, enhances  the effect of epinephrine on both  enzyme  re- 
lease and particle uptake. In fact, in the presence  of theophylline, cyclic AMP 
inhibits fl-glucuronidase release and particle uptake. The dibutyryl and 8-azido 
analogs of cyclic AMP  are more  active than  cyclic AMP  whereas  adenosine 
5'-monophosphate  is inactive. Thus,  certain  catecholamines  and  cyclic AMP 
possess  the  capacities to  inhibit/~-glucuronidase release  and  phagocytosis or 
uptake  of  zymosan  particles  by  neutrophils. 
Effect  of Cholinergic  Agents and Cyclic GMP on Release  of ~-Glucuronidase 
from  and  Particle  Uptake  by  Human  Neutrophils.--Acetylcholine,  acetyl  /~- 
methylcholine,  carbamylcholine,  and  pilocarpine markedly accelerate  release 
of/~-glucuronidase from, but not particle uptake by, human neutrophils in  the 
presence of zymosan treated with RA serum  (Table IV). Choline, a  precursor 
in  the  biosynthesis of acetylcholine, is  completely without  effect  on  enzyme 1402  HORMONAL  CONTROL OF  LYSOSOMAL ENZYME RELEASE 
TABLE III 
Effect  of Catecholamines  and  Cyclic  AMP  on  Release  of fl-Glucuronidase  from  and  Particle 
Uptake by Human Neutrophils* 
Agent(s)  tested 
Control (no agent) 
Epinephrine (E) 
[soproterenol 
Phenylephrine 
E +  propranolol (10-6M) 
E +  phentolamine (10-CM) 
E +  theophylline (10-~M) 
Cyclic AMP +  theophylline 
(10-6M) 
Dibutyryl cyclic AMP 
3-azido cyclic AMP 
AMP 
%  inhibition of/3-glucuronidase 
release 
Concn. Of 
agent: 
lO-6M 
10"-TM  IO-SM 
Particle uptake in 
IO-~M agent 
no. partides/lO0 
neutrophils 
56 
55 
12 
54 
71 
37 
m 
.4.4.1 
-4- 3.8 
0 
±0.7 
.4.2.1 
-4-6.5 
4- 
35  -4-2.2 
30  +'1.7 
0 
0 
36  -4-  2.7 
52  -4- 4.3 
19  4- 
12  -4- 
0 
0 
23  -4- 
32  4- 
505  -4- 
0.¢  386  + 
0. ~  380  4- 
512  4- 
478  -4- 
1.1 
1.(  309  -4- 
0. ~  380  -4- 
0.8  312  -4- 
1.~ 
516  + 
43  + 
62  + 
0 
2.1  22  -4-  1.8 
2.3  28  -4-  1.4 
4.7  48  -4- 3.7 
0 
9-4- 
15  -4- 
26  -4- 
0 
53 
355 
395 
66 
52 
43:~ 
34~ 
47 
* Data represent the Mean -4- SEM of three to four separate experiments.  Incubations 
of 5 X  106 neutrophils were conducted at 37°C for 15 rain in the presence of zymosan treated 
with rheumatoid arthritic serum.  Control incubations (no agents added) yielded a value of 
56.4 q- 2.7 #g phenolphthalein/18 h/5 X  106 neutrophils (19.8% of total cell activity) /or 
release  of /3-glucuronidase. Theophylline (10-6M), propranolol (10-6M),  or phentolamine 
(10-CM),  when tested alone, did not affect significantly  the release  of fl-glucuronidase. 
Significantly different  (P <  0.05) from control. 
release. Atropine, a muscarinic receptor antagonist, blocks the action of acetyl- 
choline on enzyme release. Neither hexamethonium (ganglionic blocking agent) 
nor  d-tubocurarine  (neuromuscular  blocking  agent)  affects  the  accelerating 
action of acetylcholine on enzyme release. Cyclic GMP  and its dibutyryl and 
8-bromo analogs, but not guanosine 5'-monophosphate,  also accelerate the re- 
lease of fl-glucuronidase from, but not particle uptake by, neutrophils  (Table 
IV). 
Although cholinergic agents and cyclic GMP stimulate enzyme release  from 
cells  that  are  actively  engaged  in  phagocytic  uptake  of  zymosan  particles, 
these agents do not accelerate enzyme release from cells in the absence of nor- 
mal or RA serum-treated zymosan particles. In addition, the extent of phago- 
cytic uptake  of RA  serum-treated  zymosan  particles during  a  given  15-rain 
incubation at 37°C  is not  altered by either cholinergic agents or cyclic GMP 
(Table IV).  Cell viability is maintained throughout  the  course of incubation 
with these agents,  as indicated by failure of such  agents to accelerate release L.  J.  IGNARRO, T.  F.  LINT, AND  W.  J.  GEORGE  1403 
TABLE IV 
Effect of Ckolinergic Agents and Cyclic GMP on Release of ~-Glucuronidase from and Particle 
Uptake by Human Neutrophils* 
Agent(s) tested 
Control (no agent) 
Acetylcholine (A) 
Acetyl/~-methylcholine 
Carbamylcholine 
Pilocarpine 
Choline 
A +  atropine  (10-6M) 
A +  hexamethonium 
(I0-6M) 
A +  d-tubocurarine 
(10-6M) 
Cyclic GMP 
Dibutyryl cyclic GMP 
8-bromo cyclic GMP 
GMP 
% increase in fl-glucuronidase  r~ 
Cohen.  of agent: 
lO-e  M 
121  -4- 4.1  66  -4- 
168  -4-  7.2  89  -4- 
149  -4-  7.1  76  -4- 
154  -4- 6.0  73  -4- 
0  0 
28-4- 0.8  3  4- 
129  -4- 5.7  70  -4- 
117  -4- 3.9  66  -4- 
128  -4-  7.4  75  -4- 
167  4-  9.5  98  -4- 
208  4-  11  134  -4- 
0  0 
IO-TM 
3.8 
4.3 
5.2 
4.8 
0.1 
3.4 
4.6 
Particle uptake in 
10-6M agent 
no. particles/lO0 
neutrophils 
494  -4- 44 
538  -4-  56 
520  -4- 48 
490  4-  52 
509  -4-  50 
2.8  512  -4- 42 
4.9 
8.4  536  4-  40 
516  -4- 38 
* Data represent the Mean -4- SEM of three to four separate experiments. Incubations of 
5 X  l0  s neutrophils were conducted at 37°C for 15 min in the presence of zymosan treated 
with rheumatoid arthritic serum. Control incubations (no agents added) yielded a value of 
61.5 -4- 3.8 #g phenolphthalein/18  h/5 X  l0  s neutrophils  (20.4% of total cell activity) for 
release of/~-glucuronidase. Atropine  (10-6M), hexamethonium  (10-6M),  or d-tubocurarine 
(10-6M), when tested alone, did not affect significantlv the release of/~-glucuronidase. 
of  lactate  dehydrogenase from cells and by the continual exclusion of eosin Y 
by cells (Table V). 
The  data  illustrated  in  Table  VI  indicate  that  complete  recovery  of  /~- 
glucuronidase and lactate  dehydrogenase activities  from  neutrophils and in- 
cubation media, in the presence of various test agents,  is obtained. Therefore, 
all enzyme activities are accounted for  after all incubations and the presence 
of serum-treated zymosan particles and test agents do not alter enzyme activ- 
ities appreciably. 
Effect of Autonomic Agents and Cyclic Nudeotides on Release  of ~-Glucuroni- 
dase from  Human  Neutrophils  in  the  Presence  of Zymosan-Treated  Serum.- 
Incubation of  neutrophils  with  particle-free  zymosan-treated  fresh  human 
serum results in the discharge of/~-glucuronidase but not of lactate dehydrogen- 
ase (Table VII). Treatment of human serum with zymosan probably activates 
complement, via the  alternate pathway,  and thereby generates  one or  more 
components (i.e.,  activated  fifth  component)  that  are  capable of  selectively 1404  HORMONAL  CONTROL OF  LYSOSOMAL ENZYME  RELEASE 
TABLE V 
Effect  of Cholinergic Agents  and  Cyclic GMP  on  Viability  of  Human  Neutrophils During 
Particle Uptake* 
Experimental conditioner  ReleaSedehydrogenase§Of  lactate  % of neutrophilSwith 
eosin Y uptake 
5 X  10 s neutrophils (N) 
N  -t- zymosan-RA serum (Z) 
N  -]- Z -[- 10-6M acetylcholine 
N  -[- Z -}- 10-SM carbamylcholine 
N  q- Z -{- 10-SM cyclic GMP 
N  -k Z -b 10-SM 8-bromo cyclic GMP 
0.0034  4-  0.0002  0.2  q-  0.01 
0.0039  4-  0.0004  1.1  4-  0.2 
0.0037  4.  0.0003  1.6  4-  0.3 
0.0030  -4-  0.0004  1.2  4-  0.2 
0.0034  4-  0.0003  1.9  q-  0.5 
0.0038  4-  0.0005  1.4  :k  0.1 
* Data represent the Mean ±  SEM of four separate determinations. 
:~ Incubations were conducted at 37°C for 15 rain as indicated. 
§ Expressed as Aabsorbancy  (366 nm)/min/5 X  106 neutrophils; value for total cell en- 
zyme activity was 0.126  q- 0.008. 
TABLE VI 
Recovery of Enzyme Activities from Human  Neutrophils 
Experimental condition 
Percent recovery* 
fl-glucuronidase  Lactate  dehydrogenase 
5 X  106 neutrophils (N) 
N  q- zymosan 
N  -k zymosan-normal serum 
N  q- zymosan-RA serum (Z) 
N  q- Z +  10-6M epinephrine 
N  -k Z +  10-6M cyclic AMP 
N  -k Z +  10-6M acetylcholine 
N  -b Z +  10-6M cyclic GMP 
98.4  ±  6.7  102.4  4.  2.2 
103.2  -4-  8.1  98.8  -4-  2.7 
94.1  4-  7.0  96.9  4.  2.8 
97.8  ±  4,8  101.5  ±  3.1 
106.8  q-  9.4  105.4  ±  4.4 
96.0  4.  3.9  100.8  4.  2.5 
99.6  -4-  5.4  95.8  q-  3.8 
94.2  ±  8.6  104.4  q-  4,3 
* Data represent the Mean q- SEM of three separate determinations.  Incubations were 
conducted at 37°C for 15 min as indicated.  Samples were then frozen-thawed, centrifuged, 
and the clear supernates were assayed for enzyme activities. Controls consisted of neutrophils 
that were not incubated,  and  recoveries of enzyme activities were  calculated on the basis 
of control values of total cell activities. Values for control total cell enzyme activities were: 
/~-glucuronidase,  251  4. 8.9 #g phenolphthalein/18 h/5 X  106 neutrophils; lactate dehydro- 
genase,  0.138  4. 0.009  Aabsorbancy  (366  nm)/min/5 X  106  neutrophils. 
releasing  lysosomal  enzymes  from  polymorphonuclear  leukocytes  in  the  ab- 
sence of particles  (37). Epinephrine,  but not phenylephrine,  inhibits the release 
of  /~-glucuronidase  provoked  by  zymosan-treated  serum  and  this  effect  is 
blocked  by  propranolol  (Table  VII).  Dibutyryl  cyclic  AMP,  but  not  AMP, 
also  inhibits  enzyme  release.  Conversely,  carbamylcholine,  but  not  choline, 
enhances  ~-glucuronidase  release  and  this  effect  is  blocked  by  atropine.  Di- 
butyryl cyclic GMP, but not GMP,  also enhances the discharge of ~-glucuroni- L.  J.  IGNARRO,  T.  :F.  LINT,  AND  W..1..  GEORGE  1405 
TABLE VII 
Effects of Autonomic Agents and Cyclic Neudeotides on Release of ~-Glucuronidase and Lactate 
Dehydrogenase from Human Neutrophils in  the  Presence of Zymosan-Treated Serum* 
fl-glucuronidase  Lactate 
Agent(s) tested  release  dehydrogenase release 
~g/18 h/5  X  10 s  A  absorb./min/5  X  10 s 
cells  cells 
Control  (no agent)  42.2  4-  3.8  0.0041  +  0.0005 
Epinephrine  10-6M (E)  24.1  -+-  1.7;~  0.0036  ±  0.0003 
Phenylephrine  10-6M  44.0  -~  3.4  0.0032  4-  0.0004 
E +  propranotol 10-6M  38.5  4-  2.9  0.0038  4-  0.0005 
Dibutyryl cyclic AMP 10-6M  27.0  4-  1.9,  0.0035  4-  0.0002 
AMP 10-6M  43.6  4-  3.2  0.0040  4-  0.0005 
Carbamylcholine  10-~M  (C)  96.5  4-  8.8*  0.0039  4-  0.0005 
Choline 10-6M  40.4  4-  3.8  0.0033  4-  0.0002 
C +  atropine  10-6M  53.8  4-  5.2  0.0042  4-  0.0004 
Dibutyrylcyclic GMP 10-6M  126.1  4-  11.4,  0.0046  4-  0.0005 
GMP  47.0  4-  4.2  0.0036  4-  0.0004 
* Data represent  the Mean -4- SEM  of four separate  experiments.  Incubations of 5 X 
106 neutrophils  were conducted  at 37°C for 15 min in 1.0 ml of HBSS containing  10% of 
zymosan-treated  serum (containing 0.2 M e-aminocaproic acid). Values for total cell enzyme 
activities  were 322 4- 16  (fl-glucuronidase) and  0.128 q- 0.016 (lactate  dehydrogenase). 
* Significantly different (P <  0.05) from control. 
dase.  Lactate  dehydrogenase is  not released  appreciably  nor  is  the  release  of 
this  cytoplasmic enzyme altered  by any of the  agents  tested. 
Effect of Zymosan and Epinephrine on Huma~ Neutrophil Levels of Adenosine 
3',5'-Monophosphate.--Basal  levels  of  cyclic  AMP  in  normal  human  neu- 
trophils range from 8-10 pmol per 106 purified neutrophils.  Incubation of neu- 
trophils  with  or without RA serum-treated  zymosan particles  at 37°C for up 
to  15  rain  does not  affect  the basal  levels  of cyclic AMP  (Table  VIII). Epi- 
nephrine,  in the presence of zymosan particles,  inhibits release of f~-glucuroni- 
dase and,  at the same time, elevates neutrophilic levels of cyclic AMP. In the 
absence of the zymosan,  epinephrine  does not  affect  enzyme release  and  pro- 
duces  only  a  slight  increase  in  intracellular  cyclic AMP  levels.  Propranolol, 
an  antagonist  of ~-adrenergic receptors,  reduces markedly  the  actions of epi- 
nephrine  on both enzyme release  and  cyclic AMP levels  (Table X).  Phentol- 
amine,  an  alpha-receptor  antagonist,  does  not  reduce  and,  in  fact,  enhances 
both actions of epinephrine on neutrophils. 
Effect of Zymosan and Acetylcholine on Human Neutrophil Levels of Guanosine 
3',5'-Monophosphate.--Basal  levels  of cyclic GMP  in  normal  human  neutro- 
phils  are in the range of 1-2 pmol per  106 purified neutrophils.  Incubation of 
neutrophils  with  RA  serum-treated  zymosan particles  at  37°C  for  2  and  15 
rain  results  in  elevation  of intracellular  cyclic GMP  levels  and  extracellular 
release  of/3-glucuronidase  (Table  IX).  Acetylcholine stimulates  further  both 1406  HORMONAL  CONTROL OF  LYSOSOMAL ENZYME  RELEASE 
the elevation of cyclic GMP levels (at 2 min of incubation) and the release of 
/3-glucuronidase in  the  presence of RA  serum-treated zymosan particles.  In 
the absence of zymosan acetylcholine elicits little or no effect on cyclic GMP 
levels and enzyme release. Atropine, a muscarinic receptor antagonist, greatly 
TABLE  VIII 
Effect  of  Human  Neutrophit  Interaction  with  Zymosan  and  Epinephrine  on  Intracellular 
Concentrations of Cyclic AMP* 
Experimental condition 
5 X  106 neutrophils (N) 
N  -k zymosan-RA serum (Z) 
N  -q- 10- ~M epinephrine (E) 
N-q-Z-bE 
Cyclic AMP concentration 
[ 
Incubation:  5 min  / 15 min  0 min  L 
pmol/lO s  cells 
fl-glucuronidase release 
8.9 
±0.5 
7.8 
4-0.4 
10.4 
-I-0.6 
9.9 
±0.5 
I 
Incubation:  [  5 min  15 mln  0 rain  I 
4.0 
±0.1 
18.7 
±0.8: 
4.1 
-4-0.2 
5.3 
-4-0.3§  4-2.3§ 
7.8  9.4  3.7 
±0.4  -4-0.7  ±0.1 
9.8  8.8  4.3 
±0.7  ±0.3  ±0.3 
20.7  11.4  3.5 
±1.25 -4-0.7  ±0.3 
71.3  46.1  3.7 
±4.2§ 4-3.0~  ±0.2 
~g/18  h/5  X  10 6 cells 
3.8 
±0.1 
51.2 
±4.15 
4.6 
4-0.2 
24.6 
* Data represent the Mean -4- SEM of four to six separate determinations. Incubations 
were conducted at 37°C  as indicated. 
Significantly different  (P <  0.01)  from corresponding controls  (5 X  106 neutrophils). 
§ Significantly  different  (P  <  0,05)  from  corresponding  controls  (N +  zymosan-RA 
serum). 
TABLE  IX 
Effect  of Human  Neut~ophil  Interaction  with  Zymosan  and  Acetylcholine  on Intracellular 
Concentrations of Cyclic GMP* 
Experimental condition 
5 X  106 neutrophils (N) 
N  -1- zymosan-RA serum 
(z) 
N  q-  10-SM acetylcholine 
(A) 
N-k-Z+  A 
Cyclic GMP concentration 
Incubation:  I  0 rain  2 min  10 min 
pmol/lO 6  cells 
1.67  1.08 
-4-0.36  ±0.11 
1.48  4.23 
4-0.28  ±1.46 
1.71  1.54 
±O.44  4-0.40 
1.18  9.88 
4-0.11  -I-1.68 
1.44 
±0.35 
I1.47 
±0.57: 
1.55 
±0.52 
11.67 
±0.63! 
fl-glucuronidase release 
Incubation:  I  0 min  2 rain  10 min 
3.2 
-4-0.1 
4.4 
±0.3 
4.3 
±0.2 
4.4 
±0.3 
~g/18  t*/5 X  10  6 cells 
3.9  3.8 
+0.2  ±0.2 
11.8  43.4 
±0.7~ ±3.2~ 
7.1  6.8 
±0.7  ±0.8 
50.3  94.6 
±8.8§ ±7.9§ 
* Data represent the Mean -4- SEM of four to six separate determinations. Incubations 
were  conducted  at  37°C  as  indicated. 
:~ Significantly different  (P  <  0.05)  from corresponding controls  (5 X  l0 s  neutrophils). 
§ Significantly  different  (P  <  0.001)  from  corresponding  controls  (N q-zymosan-RA 
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reduces  the  effects  of  acetylcholine  on  both  cyclic GMP  levels  and  enzyme 
release  (Table X).  Hexamethonium,  a  nicotinic receptor  antagonist,  does not 
reduce  either  effect  of  acetylcholine  on  neutrophils. 
DISCUSSION 
The model system employed for study was the interaction of purified human 
neutrophils  with  RA serum-treated  zymosan particles.  Under  the  defined  ex- 
perimental conditions the cells ingested the particles and extruded 13-glucuroni- 
dase but not lactate dehydrogenase activity. This selective discharge of gran- 
ule  contents  from phagocytic cells  without  loss  of cell  viability  has  been  re- 
ported  by other  laboratories.  Lysosomal enzyme release  during  phagocytosis 
has  been  termed  "regurgitation  during  feeding"  (38),  as  distinguished  from 
"reverse  endocytosis"  (39),  where  phagocytes  are  in  contact  with  immune 
reactants  that  have  been  rendered  nonphagocytizable  by  immobilization  to 
solid surfaces (2, 3, 5, 40). The data in the present study exemplify the former 
mechanism of enzyme release.  Extrusion  of/3-glucuronidase from neutrophils 
paralleled  closely  the  phagocytosis  of  zymosan  particles  under  various  ex- 
perimental  conditions  including  those  in  which  incubation  time,  particle/cell 
ratio  and  type of treatment  of particles  were varied. 
Zymosan particles  treated  with  seropositive  RA serum were more effective 
then particles treated with seronegative normal serum with regard to the extent 
of both particle uptake and lysosomal enzyme release. The reason for this dif- 
ference is presently unknown, but it may derive from the knowledge that fresh 
seropositive  RA  serum  contains  immune  complexes  (rheumatoid  factors,  al- 
tered IgG, and  complexes of these  abnormal proteins)  and activated  comple- 
TABLE X 
Effect  of Specific  Receptor Antagonists  on Alterations  in {3-Glucuronidase Release and  Cyclic 
Nucleotide Levels in Human Neutrophils  by A utonomic Neurohormones* 
Cyclic nucleotide concentration  Release of 
Experimental condition~  (% of control)§  /3-glucuronidase 
Cyclic AMP  Cyclic GMP  (% of control)§ 
Epinephrine,  10-6M (E) 
E +  propranolol, 10-6M 
E +  phentolamine,  10-SM 
Acetylcholine, 10-SM (A) 
A -k atropine,  10-6M 
A -1- hexamethonium,  10-SM 
321  4-  15  --  45  4- 3.1 
138  ±  17[[  --  97  -4- 4.4[[ 
546  +  37[[  --  33  4-  2.1[[ 
--  202  4-  18  251  -4-  19 
--  89  -4-  11¶  109  4-  8¶ 
--  182  -4-  16  242  4-  21 
* Data represent the Mean 4- SEM of three to five separate determinations. 
:~ Incubations with epinephrine and acetylcholine, respectively, were conducted  at 37°C 
for 10 min and 5 min. 
§ Control signifies incubation  of 5 X  106 neutrophils and the zymosan particles in 1.0 ml 
of HBSS at 37°C for 5 or 10 min. 
[] Significantly different  (P <  0.01) from the group with epinephrine  alone. 
¶ Significantly different  (P <  0.001) from the group with  acetylcholine alone. 1408  HORMONAL  CONTROL  OF  L¥SOSOMAL  ENZYME  RELEASE 
ment  components  (although  total  complement  levels  might  be  lower  than 
normal).  Zymosan particles  treated with either  heated  (56°C  for 30 min)  or 
cobra venom factor-treated  normal  serum  possessed  a  much  lower  capacity 
to provoke particle uptake and enzyme release. These data suggest that zymo- 
san-mediated particle uptake and enzyme release  require the presence of dis- 
crete complement components, since heating serum destroys the conventional 
sequence of complement activation  (41)  and  cobra venom factor inactivates 
the third component of complement in fresh serum (42, 43), thereby inhibiting 
the alternate pathway of complement activation (43). Subjection of RA serum 
to  either  heat  or  cobra venom factor before treatment  of zymosan  did  not 
reduce the actions of RA serum-treated zymosan on neutrophil function. Thus, 
it appears from these data that complement components, or the activation of 
complement  components,  are  not  required  for  RA  serum-treated  zymosan 
particles to trigger particle ingestion  and enzyme discharge.  One possible ex- 
planation for the differences between normal and RA serum is that adsorption 
onto zymosan of complex  macromolecules  such as rheumatoid factors and/or 
complexes  of rheumatoid factors and  altered IgG provides the particles with 
the  capacity to  trigger  phagocytosis and  enzyme release.  This  view is  sup- 
ported by the findings  that  phagocytosis of IgG  aggregates by leukocytes is 
enhanced by rheumatoid factors (44),  and this phagocytosis and concomitant 
lysosomal enzyme release  do not  require  the  presence  of complement  com- 
ponents (1, 6, 40). 
The inhibition  of lysosomal enzyme discharge  and particle uptake by epi- 
nephrine  and isoproterenol,  both of which are/3-adrenergic  receptor agonists, 
but not by phenylephrine,  which  is  a  specific a-adrenergic  receptor agonist, 
suggests that interaction with ~-adrenergic  receptors  associated with  the sur- 
face of the neutrophil accounts for the inhibitory actions of the catecholamines 
on neutrophil  function. This interpretation  is supported by the findings  that 
propranolol,  a  H-receptor  antagonist,  but  not  phentolamine,  an  a-receptor 
antagonist,  blocked the inhibitory action of epinephrine on phagocytosis and 
enzyme release. Enhancement of the inhibitory actions of epinephrine  by theo- 
phylline suggested that  cyclic AMP in neutrophils  might  be associated with 
these actions of the catecholamine.  Indeed,  cyclic AMP levels  in neutrophils 
were elevated markedly by epinephrine  during  phagocytosis. The close tem- 
poral relationship between inhibition  of fl-glucuronidase  discharge  and eleva- 
tion of cyclic AMP levels by epinephrine during contact of human neutrophils 
with  phagocytizable particles  further  suggests  that  the  inhibitory  action  of 
the  catecholamine  is mediated by intracellular  cyclic  AMP.  Additional  evi- 
dence in support of this hypothesis derives from the findings that ~-adrenergic 
receptor  blockade reduced  markedly  the  capacity of epinephrine  to  elevate 
cyclic AMP levels  in neutrophils.  Finally,  the addition of either  cyclic AMP 
or analogs of this nucleotide to incubation mixtures of neutrophils and zymosan 
particles resulted in inhibition of ~-glucuronidase release  and particle uptake. L.  J.  IGNARRO,  T.  F.  LINT,  AND  W.  J.  GEORGE  1409 
Cyclic AMP  levels  associated with  the neutrophils  were  not  altered signifi- 
cantly during particle uptake and release of granule enzymes in the absence of 
catecholamine. These data are in accordance with those of Manganiello et al. 
(45) and Seyberth et al. (46) which indicate that cyclic AMP levels in phago- 
cytic cells  do not increase  during particle ingestion. 
Our findings that cyclic AMP and related analogs reduced particle uptake by 
neutrophils are in agreement with those of other investigators (47-49).  These 
data could imply that inhibition of lysosomal enzyme disCharge  from phago- 
cytes by cyclic AMP is  attributed simply to inhibition of phagocytosis and, 
therefore, to the reduction of enzyme discharge from phagocytic vacuoles par- 
tially opened to the exterior of the cell. However, such a clear-cut mechanism 
may not be the only operational one as ample evidence exists that lysosomal 
enzyme release from leukocytes is  inhibited by cyclic AMP,  catecholamines 
and related agents in the absence of particle uptake (40).  Further, dibutyryl 
cyclic AMP and prostaglandin E1 reduced granule enzyme release from cyto- 
chalasin B-treated human leukocytes, under which condition particle ingestion 
is completely inhibited and, therefore, independent of enzyme release (50). Simi- 
larly, in  the present  study epinephrine  and dibutyryl cyclic AMP  inhibited 
the selective discharge of/3-glucuronidase that was provoked by particle-free, 
zymosan-treated  serum.  These  data  indicate  that  several  independent  but 
perhaps  complementary neutrophil  functions are  sensitive  to  the  inhibitory 
actions of cyclic AMP. 
In  contrast  to  the  inhibitory  action  of  catecholamines  and  cyclic AMP, 
cholinergic agents and cyclic GMP accelerated the release of/3-glucuronidase 
from phagocytizing human neutrophils. Cyclic GMP may mediate the effect 
of acetylcholine since neutrophil levels of cyclic GMP were elevated markedly 
by acetylcholine at times when release of fl-glucuronidase was also enhanced. 
The relationship between enhancement of/3-glucuronidase release and eleva- 
tion of cyclic GMP levels in human neutrophils by acetylcholine is made even 
more evident by the finding that  atropine, but not hexamethonium, greatly 
reduced both  actions of acetylcholine. This suggests that specific  muscarinic 
receptors are associated with the neutrophil surface and are responsible for the 
cholinergic stimulation of enzyme release. Neither cholinergic agents nor cyclic 
GMP  analogs altered phagocytosis at times when granule enzyme discharge 
was enhanced. Moreover, these agents enhanced enzyme release from neutro- 
phils  in  the presence  of either particle-free,  zymosan-treated serum  or  non- 
phagocytizable  particles  (40).  Thus,  both  control  as  well  as  cyclic  GMP- 
stimulated lysosomal enzyme release  can  proceed  independently of  particle 
ingestion. 
Release of ~-glucuronidase from human neutrophils during cell contact with 
immune reactant is accompanied by a  concomitant elevation of cyclic GMP 
levels. Elevation of cyclic GMP levels is associated with enhanced lysosomal 
enzyme release whether the neutrophil is "triggered" by immune reactant or 1410  HORMONAL  CONTROL  OF  LYSOSOMAL  ENZYME  RELEASE 
immunologic release of enzyme is enhanced by acetylcholine. These data sug- 
gest that intracellular cyclic GMP may serve as a second messenger in mediat- 
ing the extracellular release of neutrophilic granule contents. The concept  of 
cyclic GMP  acting as  a  second messenger is  not a  new one.  Cardiac  cyclic 
GMP has been implicated in mediating the cardiac actions of acetylcholine 
and perhaps certain other cholinergic agents (34, 51). 
At this time the precise intracellular mechanism by which endogenous nu- 
cleotides modulate the immunologic discharge of lysosomal enzymes from neu- 
trophils  is  unknown.  Cyclic AMP  and  cyclic GMP have been  shown to in- 
fluence markedly the permeability of lysosomes to enzyme proteins  (21-24). 
In view of the knowledge that cyclic AMP and cyclic GMP bind to and acti- 
vate  nucleotide-dependent  protein  kinases  and,  thereby,  stimulate  certain 
phosphorylation reactions, nucleotide-mediated phosphorylation of one or more 
subcellular components could play a role in regulating lysosomal enzyme dis- 
charge.  For  example,  intracellular phosphorylation reactions could alter  the 
physical and/or functional properties of lysosomes and interfere with specific 
functions of these organelles such as the translocation and subsequent fusion 
of granules with heterophagic vacuoles or the plasma membrane. In addition, 
or alternatively, nucleotides may alter the function of microtubule structures 
and modify the translocation of lysosome granules (1,  29, 50).  Regardless of 
the mechanism, alterations in the immunologic discharge of lysosome granule 
contents from human neutrophils by cyclic nucleotides and autonomic neuro- 
hormones suggest that these endogenous chemical agents play a role in regulat- 
ing the inflammatory process. 
SUMMARY 
The purpose of this investigation was to examine the effects of autonomic 
neurohormones,  cyclic nucleotides,  and  related  agents  on  the  immunologic 
discharge of lysosomal enzymes from, and phagocytosis by,  purified human 
neutrophils. In order to discern the possible intracellular mechanisms by which 
certain  neurohormones  influence  neutrophil  function,  the  concentrations  of 
cyclic AMP and cyclic GMP in neutrophils were assessed during cell contact 
with phagocytizable particles and autonomic agents. The model system em- 
ployed for study was the interaction of purified human neutrophils with rheu- 
matoid arthritic (RA)  serum-treated zymosan particles at 37°C in a  neutral, 
balanced salt  solution containing glucose.  Neutrophils  ingested the particles 
and discharged 13-glucuronidase but not lactate dehydrogenase activity during 
30 min of incubation. Treatment of zymosan particles with RA serum was more 
effective than treatment with normal serum with regard to the extent of both 
particle uptake and lysosomal enzyme release. During contact of neutrophils 
with  RA  serum-treated  zymosan  particles  epinephrine,  isoproterenol,  and 
cyclic AMP inhibited both particle ingestion and 15-glucuronidase  discharge. 
These actions of epinephrine were associated with a concomitant elevation of 
cyclic AMP  levels.  In  contrast  to  the  actions of catecholamines and  cyclic L.  J.  IGNARRO~ T.  F.  LINT~ AND  W.  ].  GEORGE  1411 
AMP,  acetylcholine  and  cyclic  GMP  accelerated  lysosomal  enzyme release 
without  affecting  particle  uptake.  The  actions  of  acetylcholine  were  asso- 
ciated with a concomitant elevation of cyclic GMP levels.  Increases in neutro- 
phil levels of cyclic GMP but  not of cyclic AMP were associated also with the 
discharge  of/3-glucuronidase provoked by particles  in  the  absence  of added 
cholinergic agents. The data suggest that the immunologic release of lysosomal 
enzymes from human  neutrophils  can be regulated  by autonomic  neurohor- 
mones,  perhaps  via  the  selective  formation  of  appropriate  nucleotides. 
We acknowledge the expert technical assistance of Mr. Richard J. Paddock and Mrs. Lu- 
Ann White. 
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